1. ALLA AKTIER
  2. NYHETER
  3. ACARIX

Acarix

Nyheter Acarix Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Acarix receives additional multi unit order from In-Home Concierge Practice

Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, is pleased to announce an additional multi order of the CADScor System to be utilized as a diagnostic aid for symptomatic patients suspected of coronary artery disease (CAD) by Saving Grace Concierge in the Oklahoma City and Tulsa metro areas.

 Saving Grace offers unique pediatric and adult urgent and primary care services in the privacy of a patient's home. Providers can assess, diagnose, and treat patients, offering comprehensive and compassionate healthcare with the goal of improving quality of life and promoting overall wellness. 

 "We are pleased to see such a quick repurchase of both CADScor System and patches into this novel in-home healthcare model," said Aamir Mahmood, President & CEO of Acarix.

For more information contact:
Jennifer Anderson, Head of Marketing & Communications, phone +1 720 471 4625, email jennifer.anderson@acarix.com 

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures. The CADScor System has been used on more than 29,000 patients. Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX). Carnegie Investment Bank is the Certified Advisor of Acarix. For more information, please visit www.acarix.com

Attachments
Acarix receives additional multi unit order from In-Home Concierge Practice

Datum 2024-07-08, kl 09:14
Källa MFN
Bifogade filer
Acarix receives additional multi unit order from In-Home Concierge Practice